Ruxolitinib for myelofibrosis: The earlier, the better?

Abstract

There is mounting evidence to support the use of ruxolitinib earlier in the disease course of myelofibrosis. Use in intermediate‐1 risk myelofibrosis is generally associated with higher efficacy and lower toxicity.